The role of extracellular vesicles in osteoarthritis treatment via microenvironment regulation

Han Yin1†, Muzhe Li1,2†, Guangzhao Tian1,3†, Yang Ma1, Chao Ning1, Zineng Yan1, Jiang Wu1, Qian Ge4, Xiang Sui1, Shuyun Liu1*, Jinxuan Zheng5*, Weimin Guo6* and Quanyi Guo1*

Abstract

Osteoarthritis (OA) is a degenerative joint disease that is common among the middle-aged and older populations, causes patients to experience recurrent pain in their joints and negatively affects their quality of life. Currently, therapeutic options for patients with OA consist of medications to alleviate pain and treat the symptoms; however, due to typically poor outcomes, patients with advanced OA are unlikely to avoid joint replacement. In recent years, several studies have linked disrupted homeostasis of the joint cavity microenvironment to the development of OA. Recently, extracellular vesicles (EVs) have received increasing attention in the field of OA. EVs are natural nano-microcarrier materials with unique biological activity that are produced by cells through paracrine action. They are composed of lipid bilayers that contain physiologically active molecules, such as nucleic acids and proteins. Moreover, EVs may participate in local and distal intercellular and intracellular communication. EVs have also recently been shown to influence OA development by regulating biochemical factors in the OA microenvironmental. In this article, we first describe the microenvironment of OA. Then, we provide an overview of EVs, summarize the main types used for the treatment of OA, and describe their mechanisms. Next, we review clinical studies using EVs for OA treatment. Finally, the specific mechanism underlying the application of miRNA-enriched EVs in OA therapy is described.

Keywords: Extracellular vesicles, Nanomaterials, Osteoarthritis, Microenvironment, microRNAs

Introduction

OA is a degenerative joint disease that occurs in the knee joint. OA involves structural changes in hyaline cartilage, subchondral bone, ligaments, the joint capsule, the synovial membrane, and periarticular muscles. Local damage to the articular cartilage centered on weight-bearing areas is a representative pathological feature of OA. Worldwide, 9.6% of men and 18.0% of women over 60 years of age experience OA symptoms. Approximately 80 percent of people with OA have substantially reduced mobility, and 25 percent are unable to perform major daily tasks [1]. Currently, a gold standard therapy is unavailable for OA, although surgery and medications have achieved some success in treating patients. However, the safety and risks associated with surgery, as well as the
side effects of drugs, remain clinical issues. An understanding of the pathogenic processes that drive OA might provide opportunities for future development of therapies to address this unmet clinical need.

OA is a low-grade inflammatory disease that causes cartilage degradation, synovial inflammation, subchondral bone alterations, osteophyte development, ligament degeneration, joint capsule hypertrophy, and proangiogenic characteristics [2, 3]. Synovitis refers to inflammatory alterations to the synovium, such as hyperplasia of the synovial lining, inflammatory cell infiltration, neoangiogenesis, and fibrosis [4–6]. Synovitis affects 70% of OA patients, and the severity of this condition is related to pain and cartilage loss [7, 8]. Synovial tissue from early OA patients shows elevated production of proinflammatory mediators, suggesting that acute synovitis is one of the first joint alterations to occur [9].

Many processes and substances, including transcription factors, epigenetic changes, cytokines, and proteases, govern joint tissue homeostasis, which is disturbed with OA [6]. This disturbance produces widespread alterations and prevents the synovial joint from facilitating frictionless and smooth mobility. Inflammation and thickening of synovial tissue are caused by this disruption [10], but proinflammatory mediators produced by OA immune cells from the synovium and infrapatellar fat pad (IPFP) also contribute to cartilage destruction [11]. Pattern recognition receptors such as Toll-like receptors recognize distinct pathogen-associated molecular patterns and damage-associated molecular patterns [including extracellular matrix (ECM) degeneration and products of cellular stress], prompting the cells present in the OA joint to release large amounts of inflammatory mediators. Activation of pattern recognition receptors induces cell signaling, resulting in the production of proinflammatory cytokines and chemokines such as interleukin (IL)-6, IL-8, IL-1, and tumor necrosis factor-α (TNF-α), as well as proteases such as matrix metalloproteinases (MMP)-1, MMP-3, and MMP-13, that degrade the structural components of cartilage ECM (primarily aggrecan (ACAN) and collagen) and alter chondrocyte viability and glycosaminoglycan (GAG) release [6, 11–17]. In patients with OA, large numbers of proinflammatory macrophages (M1) are activated, and these activated M1 macrophages cause further damage to the articular cartilage. Promoting the polarization of M1 macrophages to anti-inflammatory macrophages (M2) is a beneficial approach to protect articular cartilage and promote cartilage regeneration and repair. An imbalance in remodeling mediated by bone resorption by osteoclasts and bone creation by osteoblasts results in a decrease in tissue mineralization, a loss of stiffness, and thickening of the subchondral bone [18].

The abovementioned factors involved in the pathogenesis of OA cause an imbalance in the microenvironmental homeostasis of the joint cavity, which further aggravates the disease. This microenvironment has been summarized as presenting dysregulation of anti-inflammatory and proinflammatory factors, an imbalance in the immune system, disruption of the chondrogenic factor, and an increase in the amount of destructive factors (Fig. 1). Therefore, accurate regulation of the OA microenvironment and restoration of homeostasis are essential to protect articular cartilage and slow the development of OA. EVs and their regulatory potential have been the subject of many recent studies. EVs participate in cell-to-cell communication. They are produced by cells and are considered natural nano-microcarrier materials that, unlike other biological materials, inherit the biological characteristics of their precursors. EVs also have low toxicity and excellent selectivity, as well as the ability to penetrate biological membranes and transport a large number of bioactive molecules between cells. EVs were linked to OA in recent studies, as EVs regulate the inflammatory response and promote M2 macrophage polarization, cartilage production, and tissue healing [19–22]. In addition to attracting interest for other therapeutic applications, EVs may play a role in the treatment of OA by controlling the OA microenvironment. Moreover, the creation of nanomaterials based on EVs or their derivatives will be a new avenue for future cell-free OA biotherapy.

In this review, we first present the microenvironment of OA. Then, we will provide an overview of EVs and the main types of EVs used to treat OA. Finally, we review the main mechanisms of EVs in the treatment of OA.

The microenvironment of OA

OA is a disease that can affect the cartilage and surrounding tissues of any joint, although it most typically affects major joints, such as the knee, hip, and wrist. According to epidemiological data, OA affects approximately 4% of the global population, with basically no sex or geographic disparities. The annual incidence of OA-related disability accounts for 2% of all disability rates. Men are more likely than women to experience OA before the age of 45 years, while women are more likely to experience OA after the age of 45 years. The incidence increases progressively with age, reaching up to 40% or more in some areas in adults over the age of 60 years, 20% of whom will experience substantial symptoms at a certain stage. With the aging of the population, the incidence of OA will increase, thus increasing the costs of medical treatment. Therefore, to the identification of effective strategies to prevent and cure OA has become increasingly essential. The next section provides an overview of the
microenvironmental changes that occur in the joints throughout the pathogenesis of OA.

**Cytokines**
The OA microenvironment is incredibly complex, containing many different cell types that release a variety of cytokines. Macrophages, which are categorized into either the M1 or M2 type, are the most important of these cell types. A considerable imbalance in the ratio of M1 to M2 macrophages has been observed in the OA microenvironment, with an increase in the M1 population and a reduction in the M2 population, which contributes to the development of OA.

Cytokines stimulate cells, which in turn activate the local cells (synovial cells, chondrocytes, osteoblasts, osteoclasts, etc.), causing pathological changes such as cartilage degradation, vascular proliferation, and bone production through endocrine, autocrine, and paracrine signaling [23]. IL-1β and TNF-α are the most important of these cytokines. The most potent cytokine for cartilage degradation in the OA microenvironment is IL-1β [24], which is produced by chondrocytes, osteoblasts, synoviocytes, and leukocytes. IL-1β acts independently or synergistically with other cytokines to cause articular cartilage degradation and joint inflammatory responses [25]. According to Piotr Wojdasiewicz et al. [26], IL-1β activates its downstream transcription factors to promote synovial vasodilation, hyperplasia, and joint discomfort, resulting in the expression of hundreds of genes, some of which produce inflammatory mediators, including nitric oxide (NO) and prostaglandin E2 (PGE2). By inducing the generation of interstitial collagenase, matrix lysin 1 and collagenase 3 [27], and platelet-reactive protein motif-containing disintegrin-like metalloproteinases,
IL-1β disturbs chondrocytes and the ECM, damaging the cartilage structure and even inducing localized abnormalities in the articular cartilage. These changes further amplify the activity of IL-1β by inducing the production of TNF-α, other cytokines, such as IL-6 and IL-8, chemokine (C–C motif) ligand 5 (CCL5), and different adhesion molecules by chondrocytes, osteoblasts, synoviocytes, and leukocytes in an autocrine manner. IL-1β also induces the generation of reactive oxygen species (ROS) during disease progression [28], which produces different peroxides that directly degrade articular cartilage and exacerbate OA symptoms.

TNF-α is another inflammatory cytokine that triggers an inflammatory response in people with OA [29]. TNF-α stimulates the release of MMP-1, MMP-3, and MMP-13 from cartilage, the synovium, and subchondral bone layer-associated cells, resulting in a gradual decrease in the cartilage collagen and proteoglycans contents and inhibition of proteoglycan and collagen II (COL II) synthesis. These changes ultimately indirectly lead to chondrocyte death and disturb the homeostatic balance between cartilage damage and repair, resulting in varying degrees of chondrocyte death and disruption [30]. TNF-α can induce the proliferation of vascular endothelial cells by stimulating tissue expression of growth factors such as vascular endothelial growth factor, basic fibroblast growth factor, and platelet-derived growth factor, which promotes vasodilation and subchondral bone and synovial tissue proliferation and exacerbates the inflammatory symptoms of OA, as noted by Wang et al. [31]. TNF-α may also reduce the activity of the protein kinase CK2 [32]. Furthermore, TNF-α may cause chondrocyte death through both apoptosis and autophagy, worsening cartilage degradation in individuals with OA.

Cytokines have bidirectional functions in tissues such as articular cartilage, the synovium, and subchondral bone. The overexpression of cytokines may lead to the overexpression of downstream molecules such as MMPs, which can contribute to pathological alterations, including cartilage deterioration. As a result, one of the features of the OA microenvironment is the disturbance of the homeostatic equilibrium maintained by cytokines.

Proteinases
Several proteases that have been implicated in early OA articular cartilage degradation are considered diagnostic and therapeutic criteria for OA. Cellular tissues and immune cells release inflammatory mediators such as IL-1, IL-7, and TNF-α after external activation of the joint [33]. These inflammatory mediators increase the production of several proteases, such as MMPs, a disintegrin and metalloprotease (ADAM), and ADAM with thrombospondin motifs (ADAMTS), which can cause structural damage to articular cartilage and the adjacent joint tissues [34]. The major components of cartilage ECM are ACAN and COL II, which have the primary purposes of maintaining the mechanical structure and biochemical characteristics of articular cartilage.

MMPs are zinc-dependent endonucleases that regulate the composition of the cellular matrix during the normal physiological processes of the organism. MMPs are the most prominent proteases involved in the destruction of cartilage ECM in the OA microenvironment [35]. MMP-13, which is generated by chondrocytes and fibroblasts, is the most effective collagen-degrading enzyme in the MMP family [33]. Furthermore, MMP-13 is a highly active protease involved in the loss of cartilage ECM in the OA microenvironment due to its dual effects on degrading both proteoglycans and the ECM [36, 37]. As a result, the OA microenvironment overexpresses the MMP family of enzymes.

Similar to MMPs, the ADAMTS family of proteases are zinc metalloproteases with platelet-responsive protein motifs. ADAMTS gene expression contributes to the organism homeostasis under normal conditions. However, in the OA microenvironment, inflammatory cytokines such as IL-1 and TNF-α cause a significant increase in the levels of ADAMTS family members, which leads to the development of nonclassical OA inflammation via a downstream chain reaction [38]. Early cartilage deterioration in OA is assumed to involve the hydrolysis of cartilage ACAN by ADAMTS. According to the literature, ADAMTS-5, a member of the ADAMTS family of proteases, is the main hydrolase responsible for the degradation of ACAN in the ECM of OA articular cartilage [39]. Because ADAMTS is involved in total tissue regeneration, increased ADAMTS expression may be linked to not only the degeneration and deterioration of the joint but also the persistence of OA inflammation and injury, implying that OA is an uncontrolled healing process [40].

Immune cell infiltration
According to Liu et al. [41], the incidence and progression of OA may be associated with the increased infiltration of memory B cells, mast cells, and macrophages and the reduced infiltration of memory CD4 T cells and activated NK cells. By releasing inflammatory mediators and antibodies, B cells control ECM degradation [42, 43]. Mast cell-derived trypsin, according to Wang et al., causes inflammation, chondrocyte death, and cartilage degradation [44]. Proteoglycan degradation has been observed in cocultures of activated mast cells and chondrocytes, according to Woolley et al. [45]. These findings suggest that mast cells cause cartilage deterioration. De Lange-Brokaar, et al. [46] found a significantly
The term “extracellular vesicles” was first used in 2011 to characterize all extracellular structures surrounded by lipid bilayers. The three types of EVs that are classified according to their size, are ectosomes, exosomes (Exos), and apoptotic cell-derived EVs (ApoEVs). The sizes, contents, and formation mechanisms of the three types of extracellular vesicles are all different (Fig. 2). Ectosomes (100–1000 nm in diameter), comprising microvesicles (MVs), microparticles, and large and small vesicles, are very small vesicles that are expelled externally through the plasma membrane. Exos are endosomal vesicles of 50–150 nm in diameter that are produced by repetitive plasma membrane invaginations. Multivesicular bodies (MVBs) containing intraluminal vesicles (ILVs) are formed after the early creation of cup-like structures, early sorted endosomes (ESEs), and late sorted endosomes (LSEs). Both Exos and MVs have the ability to mediate intercellular communication and immunological control.

Cartilage injury and degeneration
Articular chondrocytes are dormant cells that do not multiply after maturation unless a traumatic or pathogenic event occurs [54]. Cellular degeneration is a natural aging event in which cells stop growing, regress, and lose their ability to proliferate. The lack of neovascularity in articular cartilage inhibits its capacity to regenerate, increasing the difficulty of repair after injury. The increased levels of damaging cytokines and proteases in OA cause articular cartilage erosion, extensive cartilage ECM degradation, and joint surface unevenness. Additionally, the cytokines and proteases mentioned above operate on chondrocytes, altering their biological function and hastening their degeneration and senescence. Degenerated and senescent cells produce important substances in the tissue milieu, which may alter the tissue microenvironment and damage nearby tissues, such as articular cartilage.

Overview of EVs

EVs biogenesis
Pericellular vesicles were initially discovered in mammalian tissues and bodily fluids in the late 1960s [55, 56]. The term “extracellular vesicles” was first used in 2011 to characterize all extracellular structures surrounded by lipid bilayers. The three types of EVs that are classified according to their size, are ectosomes, exosomes (Exos), and apoptotic cell-derived EVs (ApoEVs). The sizes, contents, and formation mechanisms of the three types of extracellular vesicles are all different (Fig. 2). Ectosomes (100–1000 nm in diameter), comprising microvesicles (MVs), microparticles, and large and small vesicles, are very small vesicles that are expelled externally through the plasma membrane. Exos are endosomal vesicles of 50–150 nm in diameter that are produced by repetitive plasma membrane invaginations. Multivesicular bodies (MVBs) containing intraluminal vesicles (ILVs) are formed after the early creation of cup-like structures, early sorted endosomes (ESEs), and late sorted endosomes (LSEs). Both Exos and MVs have the ability to mediate intercellular communication and immunological control.

Ectosomes and Exos are two types of EVs that are generated by healthy cells, although apoptotic cells can also release a variety of EVs. ApoEVs are divided into two types: large membrane-bound vesicles (apoptotic vesicles, 1000–5000 nm) and very small apoptotic MVs (less than 1000 nm). ApoEVs have been proven in several investigations to exhibit activities comparable to those of healthy cell-derived EVs. The primary tasks of ApoEVs include removing apoptotic cells and providing a method of intercellular communication. The therapeutic functions of EVs produced from live cells in the treatment of OA are the topic of this review.

EVs enrichment
Ultracentrifugation, gradient ultracentrifugation, coperpiration, size-exclusion chromatography, field flow fractionation, and affinity capture are the methods being used for EVs enrichment and purification. EVs have also been isolated and extracted using techniques such as microporous filtering, microfluidics, and high-performance liquid chromatography.

The prominent approach for used for EVs separation is ultracentrifugation [57]. This method feasibly separates particles with varying settling rates and then eliminates the undesired components during each centrifugation cycle by increasing the centrifugation speed and/or time in a stepwise manner. Although ultracentrifugation is the most widely used technique for EVs isolation, it has several drawbacks, including bulkiness, a requirement for expensive instrumentation, being time-consuming, carrying the risk of contamination with particles of aggregated proteins and ribonucleoproteins, and a requirement for large amounts of sample. Gradient ultracentrifugation, size-exclusion chromatography, and field flow fractionation all face
Fig. 2 The sizes, contents, and formation mechanisms of the three types of EVs. a The size ranges of three types of EVs. b EVs biogenesis. c The contents of EVs from healthy cells.
difficulties when separating particles based on particle density or size. In contrast to these physical-based isolation approaches, coprecipitation is a polymer coprecipitation-based EVs enrichment technology. Typically, this approach decreases the hydration of EVs, resulting in their precipitation. A low centrifugal force enables simple and repeatable separation of precipitated EVs products, eliminating the need for a time-consuming ultracentrifugation process [58, 59]. However, this technique is costly and lacks specificity for EVs. Multiphase polymer particles, as well as coprecipitated lipoproteins and argonaut-2 (Ago-2) RNA complexes, are common byproducts of this method. Using phase interactions between markers on the EVs surface and captured molecules linked to distinct carriers, affinity capture enables the extraction of EVs with greater purity but lower yield [60].

Each approach has benefits and drawbacks, and a combination of methods may be the best option to extract the separated EVs. The features of several EVs separation techniques are summarized in Table 1.

### EVs characterization

Isolated EVs must be properly characterized according to the International Society for Extracellular Vesicles (ISEV) minimal standard report for EVs characterization. Complete EVs characterization encompasses an assessment of both general and specific vesicle characteristics. The surface protein indicators of EVs are often characterized using Western blotting or enzyme-linked immunosorbent assay (ELISA). At least three positive and one negative EVs protein indicators should be described according to the ISEV. Moreover, at least one transmembrane/lipid binding protein (e.g., CD63 and CD9) and one cytoplasmic protein (e.g., TSG101 and ALIX) should be positive protein markers. Imaging methods and biophysical characterization are needed to characterize single vesicles. However, the only imaging techniques capable of acquiring high-resolution EVs images are electron microscopy (EM) and atomic force microscopy (AFM), which are methods that include transmission electron microscopy, scanning electron microscopy, and cryo-electron microscopy. Immunogold electron microscopy is commonly utilized to visualize the staining of certain EV markers.

#### Table 1  Overview of EVs enrichment methods

| Enrichment method         | Principle                        | Advantages                                      | Limitations                                      | Reference(s) |
|---------------------------|----------------------------------|-------------------------------------------------|-------------------------------------------------|--------------|
| Ultracentrifugation       | Density                          | The most commonly used and well-established program | Bulky                                           | [61–64]      |
|                           |                                  | Simple                                          | Requires expensive instruments                   |              |
|                           |                                  | Relatively high yield                           | Time-consuming                                  |              |
|                           |                                  |                                                  | Contamination with aggregated protein and ribonucleoprotein particles |              |
|                           |                                  |                                                  | Requires a large amount of sample                |              |
|                           |                                  |                                                  | Low purity                                       |              |
| Gradient ultracentrifugation | Based on the density gradient of the solution | Most commonly used method                        | Time-consuming                                  | [61–64]      |
|                           |                                  | Relatively high purity                          |                                                  |              |
|                           |                                  | Maintains EV integrity                          |                                                  |              |
| Size-exclusion chromatography | Particle size and molecular mass | Economic                                         | Time-consuming                                  | [63]         |
|                           |                                  | Relatively high purity                          |                                                  |              |
|                           |                                  | Maintains EV integrity                          |                                                  |              |
|                           |                                  | Multiple eluents                                 |                                                  |              |
| Field flow fractionation  | Particle size and molecular mass | High yield                                      | Lack of specificity                              | [62, 65]     |
|                           |                                  | High purity                                     |                                                  |              |
|                           |                                  | Time-efficient                                  |                                                  |              |
| Coprecipitation           | Surface charge                   | Processing that is easy to use                  | Lack of specificity                              | [66]         |
|                           |                                  |                                                  |                                                  |              |
| Affinity capture          | Based on the interaction         | High purity                                     | Difficult to produce on a large scale            | [61, 64]     |
|                           | between captured molecules and EVs antigens | Specific separation                             | Contamination                                    |              |
|                           |                                  |                                                  |                                                  |              |
pulse sensing (TRPS), dynamic light scattering (DLS), and flow cytometry (FC) are all examples of biophysical characterization techniques [67].

A light microscopic single EVs analysis approach (SEA) that enables a reliable assessment of numerous protein biomarkers in a single vesicle was described in a recent study [68]. With this method, EVs are immobilized in a microfluidic chamber, immunostained, and photographed. When vesicles are immobilized on the chip surface, the signal-to-noise ratio is generally greater than that when the vesicles are free-floating or flowing in solution. However, the chemical composition of each EVs and how EVs subpopulations are characterized are still unknown [69].

**Main EVs types used to treat OA**

**Natural EVs used in OA therapy**

Natural EVs are generally formed from unmodified mesenchymal stem cells (MSCs), which not only have the same biological functions as MSCs but also possess features that MSCs lack. As a result, EVs (including MVs and Exos) have been recommended as a replacement for standard cell-based OA treatments due to the following benefits: (1) a small size, (2) improved safety and fewer side effects due to their natural lipid and surface protein composition [70], (3) lower immunogenicity [70], and (4) protection from degradation and therapeutic site targeting of the therapeutic substances (nucleic acids and proteins) [71, 72], (5) the capacity to overcome various biological hurdles that MSCs are unable to overcome [72], (6) elimination of the need for cell injection, and (7) easy preservation procedures with fewer ethical concerns. EVs for OA research have been extracted from MSCs generated from a variety of sources, including bone marrow, adipose tissue, umbilical cords, synovial membranes/fluid, embryonic stem cells, and induced pluripotent stem cells [70]. Table 2 summarizes and compares the characteristics, size, safety, efficacy, derivation, dose, and animal models used with synovial mesenchymal stem cell-derived EVs (S-MSC-EVs), adipose-derived mesenchymal stem cell-derived EVs (AD-MSC-EVs), bone marrow mesenchymal stem cell-derived EVs (BM-MSC-EVs), and human umbilical cord mesenchymal stem cell-derived EVs (hUMSC-EVs). To make the article more rational, we also summarize the differences in MSCs isolated from different tissue sources in Table 3.

**S-MSC-EVs**

S-MSCs were extracted from the synovium surrounding a joint for the first time in 2001 [88]. S-MSCs specifically regenerate cartilage [89] and are presumed to be the most promising cells for stimulating cartilage regeneration. In vitro, S-MSCs exhibit excellent chondrogenic differentiation potential [90–92]. An intra-articular injection of S-MSCs substantially improves cartilage regeneration in experimental animal models. These cells have also been utilized to treat joint-related disorders such as OA [93–96]. According to several studies have recently, S-MSCs-EVs can successfully stimulate cartilage regeneration and delay the development of OA [73, 74, 97]. Tao et al. [73] discovered that human S-MSCs-Exosomes (S-MSCs-Exos) expressing wingless/integrated (Wnt) 5a and Wnt5b reduced ECM secretion by activating Yes-associated protein (YAP) via alternate Wnt signaling pathways while increasing chondrocyte proliferation and migration. MiR-140-5p-Exos inhibited this adverse effect by targeting RalA. In vitro, human S-MSC-140-Exos increased articular cartilage proliferation and migration without interfering with ECM secretion. However, in vivo, human S-MSC-140-Exos effectively prevented OA in a rat model. Additionally, S-MSC-Exos increased chondrocyte proliferation and migration while inhibiting apoptosis, but had no effect on ECM production or secretion, according to Wang et al. [75]. Qiu et al. discovered that miR-129-5p expression was downregulated in OA patients and IL-1-induced chondrocytes, but high mobility group protein (HMGB) 1 was substantially upregulated [76]. S-MSC-Exos enriched in miR-129-5p decreased chondrocytes apoptosis, whereas S-MSCs-Exos enhanced both the IL-1-mediated inflammatory response and apoptosis in chondrocytes. Upon further investigation of this process, miR-129-5p was shown to bind the 3’ untranslated region (3’UTR) end of HMGB1 and suppresses IL-1-mediated HMGB1 overexpression. Overall, this study revealed that miR-129-5p present in S-MSCs-Exos may prevent IL-1-induced OA by blocking HMGB1 release.

**AD-MSC-EVs**

AD-MSCs have been shown to have significant abilities to control cartilage regeneration and inflammation. They are regarded as a good source of cells for the treatment of OA [98–103]. However, the mechanism by which AD-MSCs stimulate cartilage repair is unknown. AD-MSCs control the local microenvironment mainly by secreting paracrine trophic factors, to promote repair and regeneration, reduce cartilage degradation, and enhance joint function [100]. According to Tofino-Vian et al., EVs, including MVs and Exos, mostly mediate the paracrine effects of AD-MSCs on osteoblasts in individuals with OA [77]. Wu et al. [78] examined the function of IPFP MSCs-derived Exos (MSCs-IPFP-Exos) in OA and the underlying processes. MSCs-IPFP generate large number of Exos and that these MSCs-IPFP-Exos exhibit an Exos-like morphology. MSCs-IPFP-Exos have been shown to ameliorate OA in vivo by inhibiting apoptosis. Moreover,
Table 2 Characteristics of synovial stem, adipose stem, bone marrow stem, and umbilical cord stem-derived EVs for OA

| MSCs-EV     | Derivation | Size(nm) | Characteristic | Safety                | Dose                          | Animal model                                                                 | Efficacy                                                                                   | Reference |
|-------------|------------|----------|----------------|-----------------------|-------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-----------|
| S-MSC-EVs   | Human      | 30–150   | Overexpression of miR-140-5p | Not mentioned          | 100 μL; 10¹¹ EV particles/mL | Rat knee OA model induced by cutting the medial collateral ligament and medial meniscus | Promotes the proliferation and migration of chondrocytes; inhibits the progression of OA | [73]      |
| Human       | 50–200     | Not mentioned | Not mentioned | Intravenous injection; 8 μL; 1.0 x 10¹⁰/mL | Collagenase-induced knee OA mouse model | Collagenase-induced knee OA mouse model | Promotes the proliferation and migration of chondrocytes; reduces OA progression | [74]      |
| Human       | 100–120    | Not mentioned | Not mentioned | Articular cavity injection; 30 μL; 10¹¹ EV particles/mL | Mouse OA model induced by cold water stimulation at 4 °C | Mouse OA model induced by cold water stimulation at 4 °C | Promotes chondrocyte proliferation and migration, and ECM secretion, and inhibits apoptosis; reduces OA-related damage; promotes cartilage regeneration | [75]      |
| Human       | 50–100     | Not mentioned | Not mentioned | Not mentioned | Not mentioned | Not mentioned | Reduces OA chondrocyte damage and ECM degradation | [76]      |
| AD-MSC-EVs  | Human      | 115–316  | Not mentioned | Not mentioned | Not mentioned | Not mentioned | Not mentioned | Anti-inflammatory and anti-oxidative stress activities | [77]      |
| Human       | 30–150     | Not mentioned | Not mentioned | Articular cavity injection; 10 μL; 10¹⁰ particles/mL | Induced mouse OA model generated by the destruction of the medial meniscus | Induced mouse OA model generated by the destruction of the medial meniscus | Inhibits chondrocyte apoptosis; balances anabolic and catabolic processes | [78]      |
| Human       | 185–373    | Not mentioned | Not mentioned | Not mentioned | Not mentioned | Not mentioned | Anti-inflammatory; regulates chondrocyte metabolism | [79]      |
| Human       | Average 86.46 | Not mentioned | Not mentioned | Articular cavity injection; 5 μL; 1 x 10⁸ particles | Medial meniscus instability (DMM) mouse OA model | Medial meniscus instability (DMM) mouse OA model | Prevents cartilage degeneration and attenuates OA progression; promotes chondrocyte proliferation and migration; regulates the expression of catabolic and synthetic factors; inhibits macrophage infiltration | [80]      |
| MSCs-EV  | Derivation | Size(nm) | Characteristic       | Safety | Dose                                      | Animal model                                                                 | Efficacy                                                                                           | Reference |
|----------|------------|----------|----------------------|--------|-------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|-----------|
| BM-MSC-EVs | Rat        | Average 100 | Enrichment of miR-135b | Not mentioned | Articular cavity injection; 100 μL; 1 × 10^{11} MSC-EV particles/mL | Rat knee OA model induced by cutting the medial collateral ligament and medial meniscus | Regulates cell proliferation, apoptosis, and differentiation; promotes OA cartilage repair     | [81]       |
| Rabbit   | 50–150     | Not mentioned | Not mentioned        | Not mentioned | Not mentioned                            | Not mentioned                                                                 | Inhibits chondrocyte apoptosis                                                                 | [82]       |
| Mouse    | 105.4–118.6 | Not mentioned | Not mentioned        | Not mentioned | Articular cavity injection; 250 ng/5 μL | Collagenase-induced knee OA mouse model                                                                                       | Protects cartilage and bone from degradation                                                       | [83]       |
| Rat      | 50–150     | Enrichment of miR-216a-5p | Not mentioned       | Not mentioned | Articular cavity injection; 200 μL, 200 μg of total sEV protein | Rat OA model induced by cutting the anterior cruciate ligament and eliminating the medial meniscus | Stops cartilage degeneration and attenuates OA progression; promotes chondrocyte proliferation and migration; inhibits apoptosis | [84]       |
| hUMSC-EVs | Human      | 50–150   | Enrichment of miR-23a-3p | Not mentioned | Articular cavity injection; 10 × 10^{10} particles/mL | Rat cartilage defect model                                                                                                   | Promotes cartilage regeneration                                                                  | [85]       |
| Human    | Average 120 | Enrichment of IncRNA H19 | Not mentioned        | Articular cavity injection; 200 μL; 1 mg/mL | Rat cartilage defect model |                                                                                                                                  | Promotes chondrocyte proliferation, matrix secretion, and apoptosis inhibition                      | [86]       |
| Human    | Average 120 | 3D cultivation | Not mentioned        | Articular cavity injection; 500 μL; 1 × 10^{10} particles/mL | Rat cartilage defect model                                                                                                   | Promotes chondrocyte proliferation, matrix secretion, and apoptosis inhibition                      | [87]       |
MSCs-IPFP-Exos increase matrix secretion and decrease the expression of degradation-related factors. Furthermore, by blocking the mammalian target of the rapamycin (mTOR) pathway, MSCs-IPFP-Exos may substantially increase chondrocyte autophagy. Tofio-Vian et al. [79] isolated and identified MVs from human AD-MSCs (hAD-MSCs). Then, they studied the chondroprotective role of these MVs and discovered that they reduced the production of the inflammatory mediators TNF-α, IL-6, PGE2, and NO in IL-1-stimulated OA chondrocytes. When OA chondrocytes were treated with these MVs, the measured MMP activity and MMP-13 expression were reduced, but the expression of the anti-inflammatory cytokines IL-10 and COL II increased considerably.

Woo et al. [80] examined the therapeutic potential of hAD-MSCs-derived small EVs (hAD-MSCs-sEVs) in the treatment of OA and the corresponding mechanism. hAD-MSCs-sEVs not only increased human chondrocyte proliferation and migration but also reduced the expression of MMP-1, MMP-3, MMP-13, and ADAMTS-5 by increasing COL II production in the presence of IL-1. An intra-articular injection of hAD-MSCs-sEVs dramatically slowed the development of OA and prevented cartilage degeneration in rats treated with sodium monoiodoacetate and mice with medial surgical damage.

### BM-MSCs-EVs

EVs derived from BM-MSCs have been shown to affect cell fate, including apoptosis, proliferation, invasion, and migration [104, 105]. Furthermore, BM-MSCs-EVs control many physiological and pathological processes, such as the immune response, osteogenesis, fibrosis, and angiogenesis [106–109]. In several studies, BM-MSCs-EVs were shown to stimulate the regeneration and repair of injured tissues, including cartilage and subchondral bone [107, 110–115]. Wang et al. [81] discovered that miR-135b-Exos suppress the expression of transcription factor SP1 in chondrocytes. MiR-135b-Exos promote chondrocyte proliferation and accelerate OA cartilage repair by negatively regulating Sp1 expression. This study may provide a new direction for OA treatment. Li et al. [116] investigated the effect of BM-MSCs-Exos on the etiology and behavioral symptoms of mice with lumbar facet joint OA (LFJ OA). They used BM-MSCs-Exos to treat mice with LFJ OA and detected changes in aberrant nerve invasion in the cartilage and subchondral bone. They discovered that BM-MSCs-Exos may alleviate pain by removing abnormal calcitonin gene-related peptide (CGRP)-positive nerves and abnormal H-vascular development in LFJ subchondral bone. BM-MSCs-Exos also suppress the expression of anti-tartaric acid phosphatase and activation of the receptor activator of nuclear factor-κB ligand (RANKL)-receptor activator of nuclear factor-κB (RANK)-tumor necrosis factor receptor-associated factor 6 (TRAF6) signaling pathway. In addition, subchondral bone remodeling was increased. Qi et al. [82] demonstrated that BM-MSCs-Exos can promote chondrocyte proliferation and significantly inhibit IL-1-induced chondrocyte apoptosis by inhibiting p38 and ERK1/2 phosphorylation and stimulating the Akt signaling pathway, indicating that BM-MSCs-Exos can effectively maintain chondrocyte viability in an inflammatory environment. Cosenza et al. [83] discovered that BM-MSCs-Exos and BM-MSCs-derived microparticles can protect chondrocytes from apoptosis and suppress the expression of anti-inflammatory markers (CCL2, CCL5), while increasing the expression of proinflammatory markers (iNOS, COX-2) in the presence of IL-1. These findings suggest that BM-MSCs-Exos and BM-MSCs-derived microparticles have potential therapeutic applications for the treatment of OA.

### Table 3 Comparative analysis of MSCs isolated from different tissues

| Cell types | Acquisition invasiveness | Expansion characteristics | Immune phenotype | Immunogenicity | Osteogenic differentiation capacity | Chondrogenic differentiation capacity | Adipogenic differentiation capacity |
|------------|--------------------------|--------------------------|------------------|---------------|-----------------------------------|-------------------------------------|-----------------------------------|
| S-MSCs     | Big                      | Strong                   | Express CD90, CD44, CD105 | Low           | Strong                            | Strong                              | Relatively strong                  |
| AD-MSCs    | Relatively small          | Relatively weak          | Highly express CD49d, CD54 | Low           | Weak                              | Weak                                | Weak                              |
| BM-MSCs    | Big                      | Weak                     | Highly express CD49f, PODXL | High          | Weak                              | Relatively strong                    | Strong                            |
| hUMSCs     | Small                    | Strong                   | Express CD105, CD44, CD13, CD29 | Low           | Weak                              | Relatively strong                    | Weak                              |

MSCs-IPFP-Exos increase matrix secretion and decrease the expression of degradation-related factors. Furthermore, by blocking the mammalian target of the rapamycin (mTOR) pathway, MSCs-IPFP-Exos may substantially increase chondrocyte autophagy. Tofio-Vian et al. [79] isolated and identified MVs from human AD-MSCs (hAD-MSCs). Then, they studied the chondroprotective role of these MVs and discovered that they reduced the production of the inflammatory mediators TNF-α, IL-6, PGE2, and NO in IL-1-stimulated OA chondrocytes. When OA chondrocytes were treated with these MVs, the measured MMP activity and MMP-13 expression were reduced, but the expression of the anti-inflammatory cytokines IL-10 and COL II increased considerably. Woo et al. [80] examined the therapeutic potential of hAD-MSCs-derived small EVs (hAD-MSCs-sEVs) in the treatment of OA and the corresponding mechanism. hAD-MSCs-sEVs not only increased human chondrocyte proliferation and migration but also reduced the expression of MMP-1, MMP-3, MMP-13, and ADAMTS-5 by increasing COL II production in the presence of IL-1. An intra-articular injection of hAD-MSCs-sEVs dramatically slowed the development of OA and prevented cartilage degeneration in rats treated with sodium monoiodoacetate and mice with medial surgical damage.

### BM-MSCs-EVs

EVs derived from BM-MSCs have been shown to affect cell fate, including apoptosis, proliferation, invasion, and migration [104, 105]. Furthermore, BM-MSCs-EVs control many physiological and pathological processes, such as the immune response, osteogenesis, fibrosis, and angiogenesis [106–109]. In several studies, BM-MSCs-EVs were shown to stimulate the regeneration and repair of injured tissues, including cartilage and subchondral bone [107, 110–115]. Wang et al. [81] discovered that miR-135b-Exos suppress the expression of transcription factor SP1 in chondrocytes. MiR-135b-Exos promote chondrocyte proliferation and accelerate OA cartilage repair by negatively regulating Sp1 expression. This study may provide a new direction for OA treatment. Li et al. [116] investigated the effect of BM-MSCs-Exos on the etiology and behavioral symptoms of mice with lumbar facet joint OA (LFJ OA). They used BM-MSCs-Exos to treat mice with LFJ OA and detected changes in aberrant nerve invasion in the cartilage and subchondral bone. They discovered that BM-MSCs-Exos may alleviate pain by removing abnormal calcitonin gene-related peptide (CGRP)-positive nerves and abnormal H-vascular development in LFJ subchondral bone. BM-MSCs-Exos also suppress the expression of anti-tartaric acid phosphatase and activation of the receptor activator of nuclear factor-κB ligand (RANKL)-receptor activator of nuclear factor-κB (RANK)-tumor necrosis factor receptor-associated factor 6 (TRAF6) signaling pathway. In addition, subchondral bone remodeling was increased. Qi et al. [82] demonstrated that BM-MSCs-Exos can promote chondrocyte proliferation and significantly inhibit IL-1-induced chondrocyte apoptosis by inhibiting p38 and ERK1/2 phosphorylation and stimulating the Akt signaling pathway, indicating that BM-MSCs-Exos can effectively maintain chondrocyte viability in an inflammatory environment. Cosenza et al. [83] discovered that BM-MSCs-Exos and BM-MSCs-derived microparticles can promote chondrocyte proliferation and significantly inhibit IL-1-induced chondrocyte apoptosis by inhibiting p38 and ERK1/2 phosphorylation and stimulating the Akt signaling pathway, indicating that BM-MSCs-Exos can effectively maintain chondrocyte viability in an inflammatory environment. Cosenza et al. [83] discovered that BM-MSCs-Exos and BM-MSCs-derived microparticles can promote chondrocyte proliferation and significantly inhibit IL-1-induced chondrocyte apoptosis by inhibiting p38 and ERK1/2 phosphorylation and stimulating the Akt signaling pathway, indicating that BM-MSCs-Exos can effectively maintain chondrocyte viability in an inflammatory environment. Cosenza et al. [83] discovered that BM-MSCs-Exos and BM-MSCs-derived microparticles can promote chondrocyte proliferation and significantly inhibit IL-1-induced chondrocyte apoptosis by inhibiting p38 and ERK1/2 phosphorylation and stimulating the Akt signaling pathway, indicating that BM-MSCs-Exos can effectively maintain chondrocyte viability in an inflammatory environment.

### Table 3 Comparative analysis of MSCs isolated from different tissues

| Cell types | Acquisition invasiveness | Expansion characteristics | Immune phenotype | Immunogenicity | Osteogenic differentiation capacity | Chondrogenic differentiation capacity | Adipogenic differentiation capacity |
|------------|--------------------------|--------------------------|------------------|---------------|-----------------------------------|-------------------------------------|-----------------------------------|
| S-MSCs     | Big                      | Strong                   | Express CD90, CD44, CD105 | Low           | Strong                            | Strong                              | Relatively strong                  |
| AD-MSCs    | Relatively small          | Relatively weak          | Highly express CD49d, CD54 | Low           | Weak                              | Weak                                | Weak                              |
| BM-MSCs    | Big                      | Weak                     | Highly express CD49f, PODXL | High          | Weak                              | Relatively strong                    | Strong                            |
| hUMSCs     | Small                    | Strong                   | Express CD105, CD44, CD13, CD29 | Low           | Weak                              | Relatively strong                    | Weak                              |

MSCs-IPFP-Exos increase matrix secretion and decrease the expression of degradation-related factors. Furthermore, by blocking the mammalian target of the rapamycin (mTOR) pathway, MSCs-IPFP-Exos may substantially increase chondrocyte autophagy. Tofio-Vian et al. [79] isolated and identified MVs from human AD-MSCs (hAD-MSCs). Then, they studied the chondroprotective role of these MVs and discovered that they reduced the production of the inflammatory mediators TNF-α, IL-6, PGE2, and NO in IL-1-stimulated OA chondrocytes. When OA chondrocytes were treated with these MVs, the measured MMP activity and MMP-13 expression were reduced, but the expression of the anti-inflammatory cytokines IL-10 and COL II increased considerably. Woo et al. [80] examined the therapeutic potential of hAD-MSCs-derived small EVs (hAD-MSCs-sEVs) in the treatment of OA and the corresponding mechanism. hAD-MSCs-sEVs not only increased human chondrocyte proliferation and migration but also reduced the expression of MMP-1, MMP-3, MMP-13, and ADAMTS-5 by increasing COL II production in the presence of IL-1. An intra-articular injection of hAD-MSCs-sEVs dramatically slowed the development of OA and prevented cartilage degeneration in rats treated with sodium monoiodoacetate and mice with medial surgical damage.
proliferation and migration, and inhibit apoptosis. In vitro and in vivo, kartogenin (KGN)-BM-MSCs-sEVs treatment resulted in more effective cartilage repair and matrix production than treatment with KGN [117]. In conclusion, BM-MSCs-EVs are a viable therapeutic approach for OA.

**hUMSC-EVs**

hUMSCs have the advantages of a large tissue supply, a high growth capacity, a painless collection technique and excellent biological characteristics. According to previous research, hUMSCs may develop into osteoblasts, chondrocytes, adipocytes, and a variety of other cell types [118–120]. In recent investigations, MSCs-EVs have been shown to stimulate cartilage formation [73, 121, 122]. Hu et al. [85] examined the role and mechanism of hUMSCs-sEVs in cartilage regeneration. They found that hUMSCs-sEVs could enhance chondrocyte and human bone marrow mesenchymal stem cells (hBM-MSCs) migration, proliferation, and differentiation. An miRNA microarray revealed that miR-23a-3p was the most abundant miRNAs expressed in hUMSCs-sEVs. After transferring miR-23a-3p, hUMSCs-sEVs could suppress phoshatase and tensin homolog (PTEN) expression while increasing protein kinase B (Akt) expression, therefore enhancing cartilage regeneration. Yan et al. [86] revealed that hUMSCs-Exos may function as a natural carrier of the long noncoding RNA (lncRNA) H19. The lncRNA H19 can increase chondrocyte proliferation, migration, and matrix secretion and inhibit chondrocyte death and senescence. The corresponding mechanism is that lncRNA H19-Exos compete with miR-29b-3p and upregulate forhead box O3 (FOXO3) expression in chondrocytes. An intra-articular injection of hUMSCs-Exos substantially enhances the healing of cartilage abnormalities. Furthermore, hUMSCs-Exos derived from three-dimensional (3D) culture were more beneficial for cartilage regeneration than those derived from traditional two-dimensional (2D) culture [87].

**EVs derived from other cells**

Sang et al. discovered [123] that hydrogels containing chondrocyte-derived Exos can promote cartilage regeneration and repair by controlling the levels of inflammatory factors in the OA microenvironment and polarizing macrophages. Zheng et al. [124] found that compared with IL-1β stimulated chondrocytes, Exos from normal chondrocytes can prevent the development of OA by reversing mitochondrial dysfunction and polarizing macrophages to the M2 phenotype. According to Wu et al. [125], M2 macrophage-derived Exos exert a therapeutic effect on rats with knee OA (KOA) by suppressing the PI3K/Akt/mTOR pathway and reducing the inflammatory response and pathological damage to the articular cartilage. Tan et al. [126] found that the lncRNA H19 present in fibroblast-like cell-derived Exos can target the mir-106b-5p /TIMP2 axis, increase OA chondrocyte proliferation and migration, block ECM degradation, and attenuate the development of OA.

**Engineered EVs for OA therapy**

Engineered EVs have been the focus of scientists in recent years to increase the EVs target specificity and achieve precise control. Engineered EVs outperform natural EVs in terms of therapeutic potential. Engineering procedures (Fig. 3) (e.g., transfection, coincubation, electroporation, sonication, freeze–thaw cycles, extrusion, the use of saponins) are utilized to load EVs with suitable cargo to obtain superior therapeutic effects. Many preclinical experiments analyzing EVs-based medications or molecular delivery have yielded promising results. EVs-encapsulated therapeutic molecules and medications are more stable in the circulation, traverse physiological barriers more easily and have higher biological activity and lower systemic toxicity than their corresponding free molecules. Researchers have devised novel methods to create high-purity and high-yielding EVs and to construct drug or molecule delivery systems with a high loading efficiency, targeting ability, and regulated drug or molecule release to increase the usability of EVs in OA therapy. Liang et al. combined the lysosome-associated membrane protein 2 (LAMP-2B) gene with chondrocyte affinity peptide (CAP) for transfection into dendritic cells to create chondrocyte-targeting EVs and to soften and promote cartilage regeneration. MiR-140 was then transported to chondrocytes deep in the joint [127]. Xu et al. fused the MSC-binding peptide E7 to the EVs membrane protein LAMP-2B to create EVs with E7 peptide (E7-EVs) and synovial fluid mesenchymal stem cell (SF-MSC) targeting capabilities. KGN supplied with E7-EVs enters SF-MSCs more effectively and induces a greater degree of chondrogenic differentiation than KGN provided with EVs alone without E7, indicating that these EVs might be a promising advanced OA stem cell treatment [128].

**Main mechanisms of EVs in the treatment of OA**

**Immunomodulation**

The principal function of the immune system has long been presumed to be a part of the body’s defense mechanism against viruses and the external environment. However, the immune system clearly exerts a significant effect on tissue healing. Proinflammatory cytokines, anti-inflammatory cytokines, and bidirectional factors all exist in the joint cavity, and the dynamic balance between these three variables maintains the normal physiological metabolism of articular cartilage. When this dynamic...
equilibrium is perturbed, the joint microenvironment is disrupted, which leads to the development of OA. Proinflammatory cytokines such as IL-1, IL-6, and IL-8, as well as MMP-3, are implicated in cartilage injury-induced matrix degradation and joint degeneration [129]. Proinflammatory cytokines, including IL-6 and IL-1 as well as the nuclear factor kappa B (NF-kB) pathway, have been found to exert a significant effect on synovial inflammation and cartilage degradation in OA patients. According to Xia et al. [130] and Zhao et al. [131], EVs produced from AD-MSCs were able to downregulate IL-6 expression and alter the expression of components of the NF-kB pathway.

Synovial and immunological cells, such as macrophages, produce proinflammatory cytokines and MMPs, which contribute to the development of OA [132]. According to recent research, M1 macrophages in OA synovial tissue limit MSC chondrogenic development in vitro via IL-6 [133], and M2 macrophages improve transplant cartilage survival by generating the anti-inflammatory cytokine IL-10 to decrease unfavorable inflammatory responses [134]. As a result, in cartilage regeneration therapy, the proinflammatory milieu of cartilage degeneration or OA must be controlled. Previously, macrophages were divided into two phenotypes: proinflammatory M1 and anti-inflammatory M2 phenotypes. Interferon-γ (IFN-γ), TNF-α, or pathogen-associated molecular patterns activate M1 macrophages. These activated macrophages then release proinflammatory cytokines such as IL-1, IL-6, IL-12, and iNOS. On the other hand, M2 macrophages are activated by different pathways. Transforming growth factor (TGF)-β1 and arginase-1 (Arg-1) are two growth- and angiogenesis-related substances secreted by M2 macrophages that decrease inflammation and promote tissue remodeling [135, 136]. The spatial and temporal distribution of M1 and M2 macrophages is critical to coordinate inflammation and tissue regeneration [137, 138].

MSCs-EVs produce large quantities of the anti-inflammatory cytokines IL-10 and TGF-β1 while suppressing the production of the proinflammatory mediators IL-1, IL-6, TNF-α, and IL-12 (Fig. 4). Furthermore, MSC-EVs decrease macrophage activation and promote the M1 to M2 conversion, which is important in many inflammatory illnesses. MSC-EVs exert immunomodulatory effects, according to Zhang et al. They can increase M2 macrophage infiltration into OA cartilage defects and synovial membranes, reduce M1 macrophage infiltration, and downregulate the inflammatory factors IL-1β and TNF-α, resulting in an overall decrease OA inflammatory responses [121]. Although the immunomodulatory effects of EVs on OA are unknown, the presence of
EVs in serum was recently shown to protect human OA cartilage from GAG loss in the presence of the inflammatory factor IL-1β. Additionally, the number of M2 macrophages increases following EVs therapy, increasing cartilage regeneration in immunoreactive rats, which has led to our hypothesis that MSCs-EVs might cure OA.

MSCs-EVs also exert anti-inflammatory immunomodulatory effects on T cells, NK cells and B cells. Studies have shown that MSCs-Exo exerts an anti-inflammatory effect on T cells and B cells by reducing the number of CD4+ T cells and CD8+ T cells, increasing the amount of Treg cells, and alleviating the inflammatory response of collagen-induced arthritis [139]. Moreover, MSCs-Exo can promote the transformation of effector T cells into Treg cells and increase the expression level of CTLA-4 in Treg cells. CTLA-4 is an important factor in the immunosuppressive effect of MSCs-Exo [140]. Human dendritic cells (DCs) can release large extracellular vesicles (lEVs), which can effectively induce the activation of CD4+ T cells in vitro. Among EVs secreted by immature DCs, lEVs promote the secretion of Th2 cytokines such as IL-4, IL-5 and IL-13 [141]. In addition, immature dendritic cell-derived exosomes (imDECs) can attenuate the inflammatory response and reduce the infiltration of CD4+ T cells [142]. Tumor-derived exosomes (TDEs) can inhibit the recruitment and migration of NK cells to the tumor environment, while suppressing the secretion of cytokines IFN-γ and TNF-α by NK cells, leading
to immune escape and tumor progression [143]. Studies have revealed that MSCs-Exo can inhibit the proliferation of B cells and the differentiation into immunoglobulin-secret ing plasma cells, and CCL2 in exosomes directly inhibits the secretion of immunoglobulin antibodies by plasma cells [144]. In conclusion, EVs can exert their anti-inflammatory immunomodulatory effects by regulating T cells, NK cells and B cells. However, there are currently few experimental studies on how EVs regulate T cells, NK cells, and B cells in OA, lacking sufficient basic theory, which is also the focus of the future research.

Chondrocyte regulation

Inflammation exacerbates the degeneration of damaged/diseased cartilage in OA, resulting in cell death, matrix degradation, and finally a loss of structure and function [129, 132]. Chondrocyte apoptosis is linked to cartilage deterioration and the progression of OA [32], and EVs may help prevent apoptosis in these cells [87, 121]. Cell migration and proliferation have also been reported to be facilitated by MSCs-EVs [121, 145].

Chondrocyte migration and proliferation are two critical cartilage health mechanisms that are both suppressed in OA. EVs derived from various sources have been shown to increase osteoarthritic chondrocyte proliferation, migration, and viability in a dose-dependent manner [19, 80, 82, 121, 146]. For example, as the EVs dose increases, proliferation occurs sooner; notably, a dose of 10 g of EVs was sufficient to induce chondrocyte migration. Moreover, some studies have examined the proteins involved in chondrocyte adhesion, migration, and proliferation that are regulated by EVs produced from MSCs [147, 148]. EVs alter the expression of genes such as fibroblast growth factor (FGF)-2, survivin, and Bcl2/Bax to control cell proliferation or reverse the inhibitory effects of TNF-α and IL-1β on cell migration and proliferation [87, 117, 121, 146]. By enhancing s-GAG synthesis and suppressing NO and MMP-13 production to maintain stromal homeostasis in a TMJ-OA model, hMSC-EVs attenuated the decrease in proliferation and migration. EVs derived from bone marrow stem cells, adipose stem cells, and synovial stem cells also enhance cartilage regeneration in chondrocytes by increasing GAG synthesis and COL II protein expression, and adipose stem cell-derived EVs exert the most significant effect [149]. Furthermore, these EV protein sources influence ECM stability and actin cytoskeletal dynamics, indirectly increasing chondrocyte proliferation and migration. Moreover, by releasing nucleic acids such as miRNAs, MSCs-EVs can control cell proliferation and migration. The uses of several miRNAs to treat OA are summarized in Table 4.

Induction of ECM synthesis

Changes in the composition and organization of the ECM are characteristic of OA. Because COL II and proteoglycans are two of the most important components of the ECM of articular cartilage that contribute to the formation of a healthy cartilage matrix, degradation of cartilage ECM proteins leads to cartilage degeneration [38]. MMP-13 and ADAMTS-4 and ADAMTS-5 are able to reduce the levels of COL II and proteoglycans in the OA joint cavity microenvironment. According to recent research, MSC-EVs can reverse ECM degradation by increasing the expression of matrix proteins and other cartilage formation-related genes while decreasing the levels of matrix-degrading enzymes. Tofio-Vian et al. [79] isolated and identified MVs from hAD-MSCs. When OA chondrocytes were treated with MVs, MMP activity and MMP-13 expression were reduced, but COL II expression increased considerably. Woo et al. [80] also discovered that hAD-MSC-sEVs can reduce the expression of MMP-1, MMP-3, MMP-13, and ADAMTS-5 and increase COL II production.

Many studies have recently examined the role of RNAs in MSC-EVs to control the ECM. Overexpression of miR-92a-3p in BM-MSCs-EVs increased the expression of cartilage formation-related genes such aggrecan, SRY box gene-9 (SOX9), COL9A1, COL2A1, and cartilage oligomeric matrix protein (COMP) while decreasing the expression of COL10A1, Runx-related transcription factor 2 (Runx2), and MMP-13, according to Mao et al. [151]. Protection provided by EVs is beneficial not only because of the microRNAs contained within EVs but also because of EVs proteins. S-MSC-EVs, for example, contain miR-140-5p, which restores ECM secretion by regulating RalA expression, thereby rescuing SOX9 expression [73]. However, the underlying mechanism remains a mystery. As a result, additional research is needed to confirm the aforementioned findings and determine the mechanisms of cartilage matrix catabolism and anabolism.

Microenvironmental homeostasis

MSCs have been proven to have great promise in the treatment of OA in both preclinical and clinical trials. MSCs are involved in tissue homeostasis, free radical scavenging, immunomodulation, and cell proliferation [152, 153]. Substantial data show that the therapeutic effects of MSCs are primarily mediated by paracrine pathways and that MSCs-EVs exert a critical therapeutic effect [21, 73, 121, 154, 155]. Therefore, MSC-EVs maintain homeostasis within the joint microenvironment during OA treatment (Fig. 5).
MSCs-EVs have mostly been used in mice and rats for preclinical therapy of OA and osteochondral abnormalities. MSCs-EVs suppress synovial inflammation, protect subchondral bone, reduce oxidative stress and osteoblast senescence, prevent cartilage and bone from deterioration, correct gait anomalies, stimulate cartilage regeneration, and slow OA development [19, 78, 82, 83, 121]. Table 5 summarizes the in vitro and in vivo data on MSC-EVs.

Table 4  miRNAs defined in EVs as a working biomolecule for OA therapy

| EV Source | miRNA | Selected animals model in vivo | Role | Pathway | Effect | Reference |
|-----------|-------|--------------------------------|------|---------|--------|-----------|
| UMSCs     | IncRNA H19  | SD Rats                      | Promote chondrocyte migration and matrix secretion and inhibit cell apoptosis and senescence | miR-29b-3p/FOXO3 | Promote sustained cartilage repair | [86] |
| AD-MSCs   | miR-100-5p | C57BL/6 mice                | Promote the proliferation of chondrocytes, increase the level of chondrocytes autophagy, enhance matrix synthesis, and reduce the expression of metabolic factors | mTOR signaling pathway | Protect articular cartilage from damage and ameliorate gait abnormality | [78] |
| S-MSCs    | miR-140-5p | SD rats                      | Increase the proliferation and migration of chondrocytes | Wnt signaling pathway | Successfully prevent OA | [73] |
| S-MSCs    | miR-155-5p | BALB/C mice                 | Promote the proliferation and migration of chondrocytes and inhibit cell apoptosis | Runx2 | Prevent OA | [75] |
| hBM-MSCs  | miR-136-5p | C57BL/6 mice                | Promote the migration of chondrocytes and inhibit chondrocytes degeneration | Targets ELF3 | Prevent traumatic OA | [150] |
| MSCs      | miR-135b  | SD rats                      | Promote chondrocyte proliferation and inhibit chondrocytes degeneration | Sp1 | Promote cartilage repair | [81] |
| hMSCs     | miR-206   | C57BL/6 mice                | Promote chondrocyte proliferation and inhibit chondrocyte apoptosis | KLF3-AS1/miR-206/GIT1 axis | Attenuate chondrocyte injury | [19] |

Fig. 5  MSCs-EVs target articular chondrocytes and synoviocytes to maintain homeostasis in the articular microenvironment. Cartilage degeneration, synovitis, and subchondral bone degradation are all pathological processes associated with OA. Synovial fluid component contents are altered by MSCs-EVs. Arrows pointing downward indicate downregulation, whereas arrows pointing upward indicate upregulation.

Although MSCs-EVs are comparable to MSCs in terms of treating OA and osteochondral abnormalities, they are not the same. Notably, certain drawbacks to using EVs as a clinical translation tool in regenerative medicine have been documented. First, an isolation method that maintain the qualities of EVs in the long term is unavailable. Second, the large numbers of EVs needed for animal investigations and human clinical trials are difficult to attain [158]. Only a few mice can be treated with
approximately 1–2 mg (protein content) of EVs generated from a total of approximately 60 million MSCs [145]. MSCs-EVs, on the other hand, are a simpler, safer, more practical, and easier-to-regulate OA therapeutic option than direct cell transplantation.

In conclusion, MSCs-EVs can affect intra-articular cells by controlling cartilage matrix anabolism and catabolism, subsequently enhancing the intra-articular inflammatory milieu, changing intra-articular homeostasis, and curing OA.

Clinical trial

Due to the advantages of MSC-EVs, many achievements have been reported, and clinical trials have been conducted in other disease fields, including Alzheimer's disease, lung infections, acute respiratory distress syndrome (ARDS), COVID-19, dry eye syndrome, etc. MSC-EVs will inevitably facilitate important advancements in the field of medicine in the future. However, research on the use of EVs as a biological alternative treatment is still in its early stages. The therapeutic use of EVs in the treatment of OA is limited by a variety of issues, as described below: 1. In terms of the illness itself, OA has a complicated etiology that may be caused by a number of different factors, necessitating additional research. 2. From the perspective of EVs, this industry still has certain bottleneck issues: ①for extensive pharmaceutical uses, EV isolation and purification techniques, yield, and purity have not been standardized; ②exosome composition heterogeneity and preservation are difficult problems for industrialization development and ③targeted cells internalization of EVs alters their chemical composition, making subsequent treatment results unpredictable. ④After EVs enter recipient cells, their subsequent biological distribution, pharmacokinetics and specificity of targeted delivery to the specific organ, as well as the therapeutic mechanism of OA disease, have not been fully elucidated. ⑤The location, duration of residency, and biological effects of EVs injected into the articular cavity on normal cells remain unclear. ⑥Finally, experimental support for therapy in large animals is insufficient.

Conclusions and future perspectives

The whole joint, including the cartilage and subchondral bone, is affected by OA. The microenvironment of OA is complicated, and a complete understanding of this microenvironment will be extremely helpful to treat this disease. Because of their unique roles and properties, EVs may control the microenvironmental changes that coordinate the progression of OA, hence delaying disease progression. Furthermore, EVs contain a large number of proteins, miRNAs, and other bioactive molecules that

Table 5  Efficacy and molecular mechanisms of EVs derived from MSCs used to treat OA in vivo and in vitro

| Source                  | In vivo                                                                 | In vitro                                                                 | References |
|-------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|------------|
| Human S-MSCs            | S-MSC-140-EVs treatment is superior to treatment with SMSC-EVs          | SMSC-140-EVs promote chondrocyte proliferation and migration via RalA but do not disrupt ECM secretion | [73]       |
| Human MSCs              | MSC-EVs promote cartilage repair better than EVs after IncRNA-KLF3-AS1 knockout | EVs enriched with the IncRNA KLF3-AS1 promote cell proliferation and inhibit apoptosis | [156]      |
| Rat MSCs                | TGF-β1-treated EVs promote cartilage repair to a greater extent, and miR-135b inhibitors inhibit the treatment effects | TGF-β1 promotes chondrocyte proliferation through miR-135b enriched in MSC-EVs by regulating Sp1 expression | [81]       |
| Human ESC-MSCs          | Protect cartilage and bone from degeneration                            | Exert similar chondroprotective and anti-inflammatory effects            | [21]       |
| Mouse bone marrow MSCs  | Prevent cartilage destruction and the process of OA                     | Maintain the chondroprotective phenotype by increasing COL2A1 synthesis and decreasing ADAMTS-5 expression | [83]       |
| hBM-MSCs                | MSC-92a-EVs inhibit the progression of early OA and prevent articular cartilage damage better than MSC-EVs | MSC-92a-EVs increase chondrocyte proliferation and matrix gene expression and target Wnt5A expression | [151]      |
| Human IPFP-MSCs         | Protect articular cartilage from damage and improve gait abnormalities; mir-100-5p in the EVs targets the mTOR pathway | Inhibit cell apoptosis and increase matrix synthesis partially by inhibiting mTOR to improve the level of autophagy | [78]       |
| Human MSCs              | Not mentioned                                                            | Increase the expression of COL2A1 and aggregan expression and decrease the expression of MMP-13 and Runx2 in OA chondrocytes, attenuate apoptosis in OA articular chondrocytes and IncRNA-KLF3-AS1 targeting of the miR-206/GIT1 axis in EVs | [19]       |
| Rat BM-MSCs             | The repair effects on the EV group were significantly better than those on the BMSC and model groups | EVs transfected with siRNA-Piezo1 promote the differentiation of BM-MSCs into cartilage | [157]      |
are important for tissue repair and have a wide range of therapeutic applications in the etiology, diagnosis, and treatment of OA. MSCs-EVs inherit the basic activities of their parental cells, and their therapeutic benefits mediated by immunomodulation, tissue cell repair, and regenerative effects may become a key strategy for the treatment of OA. However, these OA studies are currently focused on animal models. The processes are difficult, time-consuming, and expensive, which are the main roadblocks to their usage. As a result, more clinical trials will be required in the future to validate these findings. Engineered EVs have recently become the focus of scientific research to improve the targeting specificity of EVs and enable more precise control. Engineered EVs outperform natural EVs in terms of their therapeutic potential. The study of EVs in OA, including their role, mode of action, and diagnostic/therapeutic applications, is still in its infancy, and many questions remain unresolved. We propose that natural nanomaterial-EVs will be employed as an effective therapeutic strategy for OA patients in the future as technology advances.

Abbreviations

OA: Osteoarthritis; EVs: Extracellular vesicles; IPPF: Infrapatellar fat pad; ECM: Extracellular matrix; IL: Interleukin; TNF-α: Tumor necrosis factor-α; MMP: Matrix metalloproteinases; ACAN: Aggrecan; GAG: Glycosaminoglycan; M1: Proinflammatory macrophages; M2: Anti-inflammatory macrophages; NO: Nitric oxide; PGE2: Prostaglandin E2; CCL5: Chemokine (C–C Motif) Ligand 5; ROS: Reactive oxygen species; COL II: Collagen II; ADAM: A disintegrin and metalloproteinase; ADAMTS: ADAM with thrombospondin motifs; Exos: Exosomes; ApoEps: Apoptotic cell-derived EVs; MVs: Microvesicles; MVBS: Multivesicular bodies; ILVs: Intraluminal vesicles; ESes: Sorted endosomes; LSEs: Late sorted endosomes; Ago-2: Argonaute-2; SEV: The International Society for Extracellular Vesicles; ELISA: Enzyme-linked immunosorbent assay; EM: Electron microscopy; AFM: Atomic force microscopy; NTA: Nanoparticle tracking analysis; TRPS: Tunable resistive pulse sensing; DLS: Dynamic light scattering; FC: Flow cytometry; SEA: Single EVs analysis approach; MSCs: Mesenchymal stem cells; S-MSCs-EVs: Synovial mesenchymal stem cell-derived EVs; AD-MSC-EVs: Adipose-derived mesenchymal stem cell-derived EVs; BM-MSC-EVs: Bone marrow mesenchymal stem cell-derived EVs; hMSCs-EVs: Human umbilical cord mesenchymal stem cell-derived EVs; S-MSCs-Exos: S-MSCs-Exosomes; Wnt: Wingless / integrated; HMGB: High mobility group protein; 3'UTR: 3' untranslated region; MSCs: IPFP-Exos; IPPF MSCs-derived Exos; mTOR: Mammalian target of rapamycin; hAD-MSCs: Human AD-MSCs; hAD-MSCs-sEVs: hAD-MSCs-derived small EVs; LFI OA: Lumbar facet joint OA; CGBP: Calcinonin gene related peptide; RANKL: Receptor activator of nuclear factor-κB ligand; RANK: Receptor activator of nuclear factor-κB; TRAFs: Tumor necrosis factor receptor-associated factor 6; iNOS: Inducible nitric oxide synthase; JAK2: Janus kinase 2; KGN: Kartogenin; PTEN: Phosphatase and tensin homolog; Akt: Protein kinase B; IncRNA: Long noncoding RNA; FOXO3: Forkhead box O3; 3D: Three-dimensional; 2D: Two-dimensional; LAMP-2B: Lysosome-associated membrane protein 2; COMP: Chondrocyte affinity peptide; SF-MSC: Synovial fluid mesenchymal stem cell; NF-kB: Nuclear factor kappa B; IFN-γ: Interferon-γ; TGF: Transforming growth factor; Arg-1: Arginase-1; FGF: Fibroblast growth factor; SOX9: SRY box gene-9; COMP: Cartilage oligomeric matrix protein; Runx2: Runt-related transcription factor 2.

Acknowledgements

This work was supported by the National Key R&D Program of China (2019YFA0110600), National Natural Science Foundation of China (82102552, 81900958, 81772319), the National Science Foundation of Guangdong Province (2020A1515010050), and the China Postdoctoral Science Foundation Grant (2019M663262).

Authors’ contributions

The manuscript was mainly designed by QG, WG, JZ and SL. HY, ML and GT wrote the manuscript. YM, CN, and ZY contributed to the collection of data. JW, QG and XS revised the content of the manuscript. All authors reviewed the manuscript, contributed to its content and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors have no competing interests to declare.

Author details

1 Institute of Orthopedics, The First Medical Center, Chinese PLA General Hospital, Beijing Key Lab of Regenerative Medicine in Orthopedics, Key Laboratory of Musculoskeletal Trauma and War Injuries PLA, No. 28 Fuxing Road, Haidian District, Beijing 100853, PR China. 2 Department of Orthopedics, The First Affiliated Hospital of University of South China, Hengyang 421000, China. 3 School of Medicine, Nankai University, Tianjin 300071, China. 4 Huaiyin People’s Hospital of Huai’an, Huai’an 223001, China. 5 Department of Orthodontics, Guanghua School of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Sun Yat-Sen University, No.56 Linyuan Xi Road, Yuexiu District, Guangzhou, Guangdong 510055, People’s Republic of China. 6 Department of Orthopaedic Surgery, Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, First Affiliated Hospital, Sun Yat-Sen University, No.58 Zhongshan Second Road, Yuexiu District, Guangzhou 510080, Guangdong, China.

Received: 23 April 2022 Accepted: 18 September 2022 Published online: 05 October 2022

References

1. Lourido L, et al. Secretome analysis of human articular chondrocytes unveils catabolic effects of nicotine on the joint. Proteomics Clin Appl. 2016;10(6):671–80.

2. Mobasheri A. The future of osteoarthritis therapeutics: emerging biological therapy. Curr Rheumatol Rep. 2013;15(12):385.

3. Looiser RF, et al. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012;64(8):1697–707.

4. Szekanecz Z, et al. New insights in synovial angiogenesis. Joint Bone Spine. 2010;77(1):13–9.

5. Sellam J, Berenbaum F. Is osteoarthritis a metabolic disease? Joint Bone Spine. 2013;80(6):568–73.

6. Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone. 2012;51(2):249–57.

7. Krenn V, et al. Synovitis score: discrimination between chronic low-grade and high-grade synovitis. Histopathology. 2006;49(4):358–64.

8. Ayral X, et al. Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis – results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage. 2005;13(5):361–7.

9. Benito MJ, et al. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis. 2006;65(12):1263–7.

10. Manfredini C, et al. From osteoarthritic synovium to synovial-derived cells characterization: synovial macrophages are key effector cells. Arthritis Res Ther. 2016;18:83.
11. Schelbergen RF, et al. Alarmins S100A8 and S100A9 elicit a catabolic effect in human osteoarthritic chondrocytes that is dependent on Toll-like receptor 4. Arthritis Rheum. 2012;64(5):1477–87.
12. Chadha R. Revealed aspect of metabolic osteoarthritis. J Orthop. 2016;13(4):347–51.
13. Liu-Bryan R. Synovium and the innate inflammatory network in osteoarthritis progression. Curr Rheumatol Rep. 2013;15(5):323.
14. Sohn DH, et al. Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via Toll-like receptor 4. Arthritis Res Ther. 2012;14(1):R7.
15. Piccinin AM, Midwood KS. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm. 2010;2010:672395.
16. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373–84.
17. Kim HA, et al. The catabolic pathway mediated by Toll-like receptors in human osteoarthritic chondrocytes. Arthritis Rheum. 2006;54(7):2152–63.
18. Goldring SR, Goldring MB. Clinical aspects, pathology and pathophysiology of osteoarthritis. J Musculoskeletal Neuronal Interact. 2006;6(4):376–8.
19. Liu Y, et al. MSC-derived exosomes promote proliferation and inhibit apoptosis of chondrocytes via IncRNA-KLF3-AS1/miR-206/Gift1 axis in osteoarthritis. Cell Cycle. 2018;17(22):2241–22.
20. Mao G, et al. Exosomal miR-95-5p regulates chondrogenesis and cartilage degradation via histone deacetylase 2. J Cell Mol Med. 2018;22(11):5354–66.
21. Wang Y, et al. Exosomes from embryonic mesenchymal stem cells alleviate osteoarthritis through balancing synthesis and degradation of cartilage extracellular matrix. Stem Cell Res Ther. 2017;8(1):189.
22. Kato T, et al. Exosomes from IL-1β-stimulated synovial fibroblasts induce osteoarthritic changes in articular chondrocytes. Arthritis Res Ther. 2014;16(4):R163.
23. Rogoveanu OC, et al. Association of cytokine gene polymorphisms with osteoarthritis susceptibility. Exp Ther Med. 2018;16(3):2659–64.
24. Vincent TL. IL-1 in osteoarthritis: time for a critical review of the literature. F1000Res. 2019;8:F1000 Faculty Rev-934.
25. Attur M, et al. Low-grade inflammation in symptomatic knee osteoarthritis: prognostic value of inflammatory plasma lipids and peripheral blood leukocyte biomarkers. Arthritis Rheumatol. 2015;67(11):2005–15.
26. Wodajaszewicz P, Pioroatowski LA, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm. 2014;2014:651459.
27. Wang T, et al. Pro-inflammatory cytokines. The link between obesity and osteoarthritis. Cytokine Growth Factor Rev. 2018;44:38–50.
28. Afonso V, et al. Reactive oxygen species and superoxide dismutases: role in joint diseases. Joint Bone Spine. 2007;74(4):324–9.
29. Singh M, et al. Promoter polymorphisms in IL-6 gene influence apoptosis of chondrocytes via lncRNA-KLF3-AS1/miR-206/GIT1 axis in osteoarthritis. Arthritis Res Ther. 2006;8(1):R27.
30. Kim HR, et al. Macrophage migration inhibitory factor upregulates angiogenic factors and correlates with clinical measures in rheumatoid arthritis. J Biol Chem. 2017;292(5):1625–36.
human colon cancer cell line LIM1863-derived exosomes. Methods. 2012;56(2):293–304.

65. McNamara RP, et al. Large-scale, cross-flow based isolation of highly pure and endotoxins-competent extracellular vesicles. J Extracell Vesicles. 2018;7(1):154358.

66. Shao H, et al. New Technologies for Analysis of Extracellular Vesicles. Chem Rev. 2018;118(4):1917–50.

67. Thery C, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):153570.

68. Lee K, et al. Multiplexed Profiling of Single Extracellular Vesicles. ACS Nano. 2018;11(2):494–503.

69. Varderidou-Milasian S, Lorenzowicz MJ. Mesenchymal stromal/stem cell-derived extracellular vesicles in tissue repair: challenges and opportunities. Theranostics. 2020;10(13):5979–97.

70. Kim GB, et al. Mesenchymal Stem Cell-Derived Exosomes and Their Therapeutic Potential for Osteoarthritis. Biology (Basel). 2021;10(4):285.

71. Mendi M, et al. Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight. 2018;3(8):e99263.

72. Alvarez-Erviti L, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341–6.

73. Tao SC, et al. Exosomes derived from miR-140-5p-overexpressing human synovial mesenchymal stem cells enhance cartilage tissue regeneration and prevent osteoarthritis of the knee in a rat model. Theranostics. 2017;7(11):180–95.

74. Zhu Y, et al. Comparison of exosomes secreted by induced pluripotent stem cell-derived mesenchymal stem cells and synovial membrane-derived mesenchymal stem cells for the treatment of osteoarthritis. Stem Cell Res Ther. 2017;8(1):64.

75. Wang Z, et al. Exosomes derived from miR-155-5p-overexpressing synovial mesenchymal stem cells prevent osteoarthritis via enhancing proliferation and migration, attenuating apoptosis, and modulating extracellular matrix secretion in chondrocytes. Cell Biol Toxicol. 2021;37(1):85–96.

76. Qiu M, Liu D, Fu Q. MiR-129–5p shuttled by human synovial mesenchymal stem cells downregulates the ITGA2 gene in osteoarthritis. J Cell Physiol. 2019;234(11):21380–94.

77. Tang Y, et al. Exosomes derived from miR-129–5p/FoxO3 axis. Clin Transl Med. 2021;11(1):e255.

87. Yan L, Wu X. Exosomes produced from 3D cultures of umbilical cord mesenchymal stem cells in a hollow-fiber bioreactor show improved osteochondral regeneration activity. Cell Biol Toxicol. 2020;36(2):165–78.

88. De Bari C, et al. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum. 2001;44(8):1928–42.

89. Jones BA, Pei M. Synovium-derived stem cells: a tissue-specific stem cell for cartilage engineering and regeneration. Tissue Eng Part B Rev. 2012;18(4):301–11.

90. Miyamoto C, et al. Osteogenic protein-1 with transforming growth factor-beta1: potent inducer of chondrogenesis of synovial mesenchymal stem cells in vitro. J Orthop Sci. 2007;12(6):555–61.

91. Kurth T, et al. Chondrogenic potential of human synovial mesenchymal stem cells in alginate. Osteoarthritis Cartilage. 2007;15(10):1178–89.

92. Shirasawa S, et al. In vitro chondrogenesis of human synovium-derived mesenchymal stem cells: optimal condition and comparison with bone marrow-derived cells. J Cell Biochem. 2006;97(1):84–97.

93. Kondo S, et al. Transplantation of Aggregates of Autologous Synovial Mesenchymal Stem Cells for Treatment of Cartilage Defects in the Femoral Condyle and the Femoral Groove in Microminipigs. Am J Sports Med. 2019;47(10):2383–47.

94. Enomoto T, et al. Timing of Intra-Articular Injection of Synovial Mesenchymal Stem Cells Affects Cartilage Restoration in a Partial Thickness Cartilage Defect Model in Rats. Cartilage. 2020;11(1):122–9.

95. Mak J, et al. Intra-articular injection of synovial mesenchymal stem cells improves cartilage repair in a mouse injury model. Sci Rep. 2016;6:23076.

96. Ozeki N, et al. Not single but periodic injections of synovial mesenchymal stem cells maintain viable cells in knees and inhibit osteoarthritis progression in rats. Osteoarthritis Cartilage. 2016;24(6):1061–70.

97. Koizumi K, et al. Synovial mesenchymal stem cells from osteo- or rheumatoid arthritis joints exhibit good potential for cartilage repair using a scaffold-free tissue engineering approach. Osteoarthritis Cartilage. 2016;24(8):1413–22.

98. Lee WS, et al. Intra-Articular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis: A Phase Ib, Randomized, Placebo-Controlled Clinical Trial. Stem Cells Transl Med. 2019;8(6):504–11.

99. Kim YS, Koh YG. Comparative Matched-Pair Analysis of Open-Wedge High Tibial Osteotomy With Versus Without an Injection of Adipose-Derived Mesenchymal Stem Cells for Varus Knee Osteoarthritis: Clinical and Second-Look Arthroscopic Results. Am J Sports Med. 2018;46(1):2669–77.

100. Damia E, et al. Adipose-Derived Mesenchymal Stem Cells: Are They a Good Therapeutic Strategy for Osteoarthritis? Int J Mol Sci. 2018;19(7):1926.

101. Skalska U, Kontry E. Adipose-derived mesenchymal stem cells from infrapatellar fat pad of patients with rheumatoid arthritis and osteoarthritis have comparable immunomodulatory properties. Autoimmunity. 2016;49(2):124–31.

102. Maumus M, et al. Adipose-derived mesenchymal stem cells protect chondrocytes from degeneration associated with osteoarthritis. Stem Cell Res. 2013;11(2):834–44.

103. Manferdini C, et al. Adipose-derived mesenchymal stem cells exert antiinflammatory effects on chondrocytes and synoviocytes from osteoarthritic patients through prostaglandin E2. Arthritis Rheum. 2013;65(S5):S1271–81.

104. Xu Y, et al. microRNA-16-5p-containing exosomes derived from bone marrow-derived mesenchymal stem cells inhibit proliferation, migration, and invasion, while promoting apoptosis of colorectal cancer cells by downregulating ITGA2. J Cell Physiol. 2019;234(11):21380–94.

105. Xie C, et al. Exosomes derived from microRNA-101-3p-overexpressing human bone marrow mesenchymal stem cells suppress oral cancer cell proliferation, invasion, and migration. Mol Cell Biochem. 2019;458(1–2):11–26.

106. Zhang L, et al. Exosomes from bone marrow mesenchymal stem cells enhance fracture healing through the promotion of osteogenesis and angiogenesis in a rat model of nonunion. Stem Cell Res Ther. 2020;11(1):38.

107. Zhao C, et al. Exosomes Derived From Bone Marrow Mesenchymal Stem Cells Inhibit Complement Activation In Rats With Spinal Cord Injury. Drug Des Devel Ther. 2019;13:3693–704.
108. Yong X, et al. Human bone marrow mesenchymal stem cells-derived exosomes alleviate liver fibrosis through the Wnt/beta-catenin pathway. Stem Cell Res Ther. 2019;10(1):98.

109. He JS, et al. Exosomes Derived from IDO1-Overexpressing Rat Bone Marrow Mesenchymal Stem Cells Promote Immunosuppression of Cardiac Allografts. Cell Transplant. 2018;27(11):1657–83.

110. Xiong L, et al. Exosomes from Bone Marrow Mesenchymal Stem Cells Can Alleviate Early Brain Injury After Subarachnoid Hemorrhage Through mRNA129-3p-HMG1B Pathway. Stem Cells Dev. 2020;29(4):212–21.

111. Mianehsaz E, et al. Mesenchymal stem cell-derived exosomes: a new therapeutic approach to osteoarthritis? Stem Cell Res Ther. 2019;10(1):340.

112. Asghar S, et al. Exosomes in intercellular communication and implications for osteoarthritis. Rheumatology (Oxford). 2020;59(1):57–68.

113. Ding J, et al. Exosomes Derived from Human Bone Marrow Mesenchymal Stem Cells Stimulated by Deferoxamine Accelerate Cutaneous Wound Healing by Promoting Angiogenesis. Biomed Res Int. 2019;2019:9742765.

114. Zhu G, et al. Exosomes from human-bone-derived mesenchymal stem cells protect against renal ischemia/reperfusion injury via transferring miR-199a-3p. J Cell Physiol. 2019;234(2):2373–49.

115. Zhao L, et al. Exosomes derived from bone marrow mesenchymal stem cells overexpressing microRNA-25 protect spinal cords against transient ischemia. J Thorac Cardiovasc Surg. 2019;157(2):508–17.

116. Li J, et al. BMSCs-Derived Exosomes Ameliorate Pain Via Abrogation of Aberrant Nerve Invasion in Subchondral Bone in Lumbar Facet Joint Osteoarthritis. J Orthop Res. 2020;38(3):670–9.

117. Liu C, et al. Kartogenin enhances the therapeutic effect of bone marrow mesenchymal stem cells derived exosomes in cartilage repair. Nanomedicine (Lond). 2020;15(3):273–88.

118. Zhang YN, Lie PC, Wei X. Differentiation of mesenchymal stromal cells into low immunogenic hepatocyte-like cells. Cytotherapy. 2009;11(5):548–58.

119. Zhao Q, et al. Differentiation of human umbilical cord mesenchymal stromal cells into low immunogenic hepatocyte-like cells. Cytotherapy. 2009;11(4):414–26.

120. Ji GZ, Wei X, Chen GQ. Growth of human umbilical cord Wharton's Jelly-derived mesenchymal stem cells on the terpolyester poly(3-hydroxybutyrate-co-3-hydroxyvalerate-co-3-hydroxyhexanoate). J Biomater Sci Polym Ed. 2009;20(3):325–39.

121. Zhang S, et al. MSC exosomes mediate cartilage repair by enhancing proliferation, attenuating apoptosis and modulating immune reactivity. Biomaterials. 2018;156:16–27.

122. Liu X, et al. Integration of stem cell-derived exosomes with in situ hydrogel glue as a promising tissue patch for articular cartilage regeneration. Nanoscale. 2017;9(13):4430–8.

123. Sang X, et al. Thermosensitive Hydrogel Loaded with Primary Chondrocyte-Derived Exosomes Promotes Cartilage Repair by Regulating Macrophage Polarization in Osteoarthritis. Tissue Eng Regen Med. 2022;19(3):629–42.

124. Chen X, et al. Mesenchymal Stomal/stem Cell-Derived Extracellular Vesicles Promote Human Cartilage Regeneration In Vitro. Theranostics. 2018;8(4):906–20.

125. Ragni E, et al. Secreted Factors and EV-miRNAs Orchestrate the Healing Capacity of Adipose Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis. Int J Mol Sci. 2020;21(15):1582.

126. Chen P, et al. Desktop-stereolithography 3D printing of a radially oriented extracellular matrix/mesenchymal stem cell exosome bioink for osteochondral defect regeneration. Theranostics. 2019:8(9):4239–59.

127. Li Q, et al. The tissue origin effect of extracellular vesicles on cartilage and bone regeneration. Acta Biomater. 2021;125:253–66.

128. Chen X, et al. Exosomes derived from M2 macrophage M1 polarisation exacerbate experimental osteoarthritis partially through R-spondin-2. Ann Rheum Dis. 2018;77(10):1524–34.

129. Cosenza S, et al. Mesenchymal stem cells-derived exosomes are more immunosuppressive than microparticles in inflammatory arthritis. Theraonotics. 2018;8(5):1399–410.

130. Chen W, et al. Immunomodulatory effects of mesenchymal stromal cells-derived exosome. Immunol Res. 2016;64(4):821–30.

131. Tkach M, et al. Qualitative differences in T-cell activation by dendritic cell-derived extracellular vesicle subtypes. EMBO J. 2017;36(20):3012–28.

132. Li JS, Fang W, Vangsness CT Jr. Implications of Anti-Inflammatory Nature of Exosomes in Knee Arthritis. Cartilage. 2021;13(2_suppl):204S-212S.

133. Xia B, et al. Osteoarthritis pathogenesis: a review of molecular mechanisms. Calcif Tissue Int. 2014;95(6):495–505.

134. Zhao C, et al. Exosomes from adipose-derived stem cells promote chondrogenesis and suppress inflammation by upregulating miR145 and miR221. Mol Med Rep. 2020;21(4):1881–9.

135. Asghar S, et al. Exosomes in intercellular communication and implications for osteoarthritis. Rheumatology (Oxford). 2020;59(1):57–68.

136. Zhang X, et al. Exosomes Derived from M2 Macrophages Exert a Protective Effect Against Osteoarthritis. Tissue Eng Regen Med. 2014;11(28):1167–75.

137. Ding J, et al. Exosomes: a new therapeutic approach to osteoarthritis? Stem Cell Res Ther. 2019;10(1):340.

138. Zheng L, et al. Primary chondrocyte exosomes mediate osteoarthritis progression by regulating mitochondrial reactive oxygen species. Nanomedicine (Lond). 2019;14(24):3193–212.

139. Da-Wa ZM, et al. Exosomes Derived from M2 Macrophages Exert a Therapeutic Effect Via Inhibition of the PI3K/AKT/mTOR Pathway in Rats with Knee Osteoarthritis: Biomed Res Int. 2021;2021:7218067.

140. Tan F, Wang D, Yuan Z. The Fibroblast-Like Synovocyte Derived Exosomal Long Non-coding RNA H19 Alleviates Osteoarthritis Progression Through the miR-106b-5p/TIMP2 Axis. Inflammation. 2020;204(6):1498–509.

141. Li JS, et al. Single intrarticular dexamethasone injection immediately post-surgery in a rabbit model mitigates early inflammatory responses and post-traumatic osteoarthritis-like alterations. J Orthop Res. 2015;33(12):1826–34.

142. He JS, et al. Exosomes Derived from IDO1-Overexpressing Rat Bone Marrow Mesenchymal Stem Cells Promote Immunosuppression of Cardiac Allografts. Cell Transplant. 2018;27(11):1657–83.

143. Zhao L, et al. Exosomes from Bone Marrow Mesenchymal Stem Cells Can Alleviate Early Brain Injury After Subarachnoid Hemorrhage Through mRNA129-3p-HMG1B Pathway. Stem Cells Dev. 2020;29(4):212–21.

144. Mianehsaz E, et al. Mesenchymal stem cell-derived exosomes: a new therapeutic approach to osteoarthritis? Stem Cell Res Ther. 2019;10(1):340.

145. Asghar S, et al. Exosomes in intercellular communication and implications for osteoarthritis. Rheumatology (Oxford). 2020;59(1):57–68.

146. Zhang X, et al. Exosomes Derived from M2 Macrophages Exert a Therapeutic Effect Via Inhibition of the PI3K/AKT/mTOR Pathway in Rats with Knee Osteoarthritis: Biomed Res Int. 2021;2021:7218067.

147. Fang W, Vangsness CT Jr. Implications of Anti-Inflammatory Nature of Exosomes in Knee Arthritis. Cartilage. 2021;13(2_suppl):204S-212S.

148. Zhao C, et al. Osteoarthritis pathogenesis: a review of molecular mechanisms. Calcif Tissue Int. 2014;95(6):495–505.

149. Zhao C, et al. Exosomes from adipose-derived stem cells promote chondrogenesis and suppress inflammation by upregulating miR145 and miR221. Mol Med Rep. 2020;21(4):1881–9.

150. Asghar S, et al. Exosomes in intercellular communication and implications for osteoarthritis. Rheumatology (Oxford). 2020;59(1):57–68.

151. Xu X, et al. Exosome-mediated delivery of kartogenin for chondrogenesis of synovial fluid-derived mesenchymal stem cells and cartilage regeneration. Biomaterials. 2021;269:120539.

152. He JS, et al. Exosomes Derived from IDO1-Overexpressing Rat Bone Marrow Mesenchymal Stem Cells Promote Immunosuppression of Cardiac Allografts. Cell Transplant. 2018;27(11):1657–83.
156. Liu Y, et al. Exosomal KLF3-AS1 from hMSCs promoted cartilage repair and chondrocyte proliferation in osteoarthritis. Biochem J. 2018;475(22):3629–38.

157. Li LL, et al. Repair of osteoarthritis in animal model with exosomes derived from BMSCs transfected by the siRNA -Piezo1 through CT navigation. Zhongguo Gu Shang. 2021;34(12):1171–8.

158. Katsuda T, et al. The therapeutic potential of mesenchymal stem cell-derived extracellular vesicles. Proteomics. 2013;13(10–11):1637–53.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.